Nenad Bogdanovic

List of Publications by Year
in descending order

56 papers	2,882 citations	218677 26 h-index	189892 50 g-index
61 all docs	61 docs citations	61 times ranked	4509 citing authors

#	Article	IF	Citations
1	Serum Amyloidogenic Nanoplaques and Cytokines in Alzheimerâ€™s Disease: Pilot Study in a Small Naturalistic Memory Clinic Cohort. Journal of Alzheimer's Disease, 2022, 86, 1459-1470.	2.6	4
2	Vitamin D in Alzheimerâ€™s Disease: Low Levels in Cerebrospinal Fluid Despite Normal Amounts in Serum. Journal of Alzheimer's Disease, 2022, 86, 1301-1314.	2.6	5
3	Amyloid, tau, and astrocyte pathology in autosomal-dominant Alzheimerâ€™s disease variants: AÎ²PParc and PSEN1DE9. Molecular Psychiatry, 2021, 26, 5609-5619.	7.9	16
4	Associations of cerebrospinal fluid amyloidogenic nanoplaques with cytokines in Alzheimerâ€™s disease. Translational Neurodegeneration, 2021, 10, 18.	8.0	6
5	Confusion, cognitive impairment, and spinal cord compression caused by plasmacytoma: a case report. BMC Neurology, 2021, 21, 303.	1.8	0
6	Vitamin D Levels, APOE Allele, and MRI Volumetry Assessed by NeuroQuant in Norwegian Adults with Cognitive Symptoms. Journal of Alzheimer's Disease, 2021, 79, 311-321.	2.6	8
7	Diagnostic accuracy and clinical applicability of the Swedish version of the 4AT assessment test for delirium detection, in a mixed patient population and setting. BMC Geriatrics, 2021, 21, 568.	2.7	6
8	Microdissected Pyramidal Cell Proteomics of Alzheimer Brain Reveals Alterations in Creatine Kinase B-Type, 14-3-3-Î³, and Heat Shock Cognate 71. Frontiers in Aging Neuroscience, 2021, 13, 735334.	3.4	4
9	Lack of fibrillar amyloid plaques but hypometabolism and astrogliosis in autosomal dominant variant AÃŸPParc Alzheimerâ€™s disease. Molecular Psychiatry, 2021, 26, 5471-5471.	7.9	0
10	The Proteome of the Dentate Terminal Zone of the Perforant Path Indicates Presynaptic Impairment in Alzheimer Disease. Molecular and Cellular Proteomics, 2020, 19, 128-141.	3.8	22
11	Amyloidogenic Nanoplaques in Cerebrospinal Fluid: Relationship to Amyloid Brain Uptake and Clinical Alzheimerâ€™s Disease in a Memory Clinic Cohort. Journal of Alzheimer's Disease, 2020, 77, 831-842.	2.6	3
12	Amyloidogenic nanoplaque levels are increased in the cerebrospinal fluid in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e042828.	0.8	0
13	Comparison of Cerebrospinal Fluid Amyloidogenic Nanoplaques With Core Biomarkers of Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2020, 12, 608628.	3.4	3
14	Insulin-Independent and Dependent Glucose Transporters in Brain Mural Cells in CADASIL. Frontiers in Genetics, 2020, 11, 1022.	2.3	4
15	Amyloid-Î² PETâ€”Correlation with cerebrospinal fluid biomarkers and prediction of AlzheimerÂ´s disease diagnosis in a memory clinic. PLoS ONE, 2019, 14, e0221365.	2.5	37
16	Amyloidogenic Nanoplaques in Blood Serum of Patients with Alzheimerâ€™s Disease Revealed by Time-Resolved Thioflavin T Fluorescence Intensity Fluctuation Analysis. Journal of Alzheimer's Disease, 2019, 68, 571-582.	2.6	21
17	Clinical impact of [18F]flutemetamol PET among memory clinic patients with an unclear diagnosis. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1276-1286.	6.4	38
18	Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein. Scientific Reports, 2019, 9, 2460.	3.3	7

#	Article	IF	Citations
19	Progression to dementia in memory clinic patients with mild cognitive impairment and normal Î²-amyloid. Alzheimer's Research and Therapy, 2019, 11, 99.	6.2	23
20	Hippocampal expression of cellâ€adhesion glycoprotein neuroplastin is altered in Alzheimer's disease. Journal of Cellular and Molecular Medicine, 2019, 23, 1602-1607.	3.6	23
21	Finding of increased caudate nucleus in patients with Alzheimer's disease. Acta Neurologica Scandinavica, 2018, 137, 224-232.	2.1	47
22	Effects of Alcohol Abuse on Proliferating Cells, Stem/Progenitor Cells, and Immature Neurons in the Adult Human Hippocampus. Neuropsychopharmacology, 2018, 43, 690-699.	5.4	44
23	Meta-analysis of Alzheimerâ€™s disease on 9,751 samples from Norway and IGAP study identifies four risk loci. Scientific Reports, 2018, 8, 18088.	3.3	47
24	Hippocampal granule cell loss in human chronic alcohol abusers. Neurobiology of Disease, 2018, 120, 63-75.	4.4	28
25	Maturation and processing of the amyloid precursor protein is regulated by the potassium/sodium hyperpolarization-activated cyclic nucleotide-gated ion channel 2 (HCN2). Biochemical and Biophysical Research Communications, 2017, 483, 352-358.	2.1	8
26	Amyloid tracers binding sites in autosomal dominant and sporadic Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 419-430.	0.8	31
27	Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with Î³-secretase and regulates neuronal amyloid Î²-peptide levels. Alzheimer's Research and Therapy, 2017, 9, 57.	6.2	164
28	Re: Glemsk og glemt. Tidsskrift for Den Norske Laegeforening, 2017, 137, 685-685.	0.2	0
29	Preclinical Amyloid-Î² and Axonal Degeneration Pathology in Delirium. Journal of Alzheimer's Disease, 2016, 55, 371-379.	2.6	35
30	Excellent outcome of pallidal deep brain stimulation in DYT6 dystonia: A case report. Journal of the Neurological Sciences, 2016, 366, 18-19.	0.6	9
31	Neuropeptide S- and Neuropeptide S receptor-expressing neuron populations in the human pons. Frontiers in Neuroanatomy, 2015, 9, 126.	1.7	31
32	Reduced Sympathetic Response to Head-Up Tilt in Subjects with Mild Cognitive Impairment or Mild Alzheimer's Dementia. Dementia and Geriatric Cognitive Disorders Extra, 2015, 5, 107-115.	1.3	23
33	Neuropathological assessments of the pathology in frontotemporal lobar degeneration with TDP43-positive inclusions: an inter-laboratory study by the BrainNet Europe consortium. Journal of Neural Transmission, 2015, 122, 957-972.	2.8	25
34	Cerebral ABC Transporter-common Mechanisms May Modulate Neurodegenerative Diseases and Depression in Elderly Subjects. Archives of Medical Research, 2014, 45, 738-743.	3.3	27
35	P3-041: BRAIN DEPOSITION OF PYROGLUTAMATE AÎ² IN AÎ² AMYLOIDOSIS. , 2014, 10, P643-P643.		0
36	The Arctic AÎ²PP mutation leads to Alzheimerâ€™s disease pathology with highly variable topographic deposition of differentially truncated AÎ². Acta Neuropathologica Communications, 2013, 1, 60.	5.2	38

#	Article	IF	Citations
37	Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology, 2012, 79, 229-236.	1.1	138
38	The Arctic amyloid-Î² precursor protein (AÎ²PP) mutation results in distinct plaques and accumulation of N- and C-truncated AÎ². Neurobiology of Aging, 2012, 33, 1010.e1-1010.e13.	3.1	31
39	Identification of two novel synaptic Î³-secretase associated proteins that affect amyloid Î²-peptide levels without altering Notch processing. Neurochemistry International, 2012, 61, 108-118.	3.8	22
40	Analysis of microdissected human neurons by a sensitive ELISA reveals a correlation between elevated intracellular concentrations of AÎ²42 and Alzheimerâ€™s disease neuropathology. Acta Neuropathologica, 2010, 119, 543-554.	7.7	61
41	Environmental enrichment alters dentate granule cell morphology in oldestâ€old rat. Journal of Cellular and Molecular Medicine, 2009, 13, 1845-1856.	3.6	25
42	Assessment of Î²-amyloid deposits in human brain: a study of the BrainNet Europe Consortium. Acta Neuropathologica, 2009, 117, 309-320.	7.7	143
43	Staging/typing of Lewy body related Î±-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathologica, 2009, 117, 635-652.	7.7	249
44	Staging of Neurofibrillary Pathology in Alzheimer's Disease: A Study of the BrainNet Europe Consortium. Brain Pathology, 2008, 18, 484-496.	4.1	361
45	Clinical and Neuropathological Features of the Arctic APP Gene Mutation Causing Early-Onset Alzheimer Disease. Archives of Neurology, 2008, 65, 499.	4.5	91
46	Assessment of Î±-Synuclein Pathology: A Study of the BrainNet Europe Consortium. Journal of Neuropathology and Experimental Neurology, 2008, 67, 125-143.	1.7	73
47	Amyloid Î²-peptide levels in laser capture microdissected cornu ammonis 1 pyramidal neurons of Alzheimer's brain. NeuroReport, 2008, 19, 1085-1089.	1.2	45
48	Analysis of Single Alzheimer Solid Plaque Cores by Laser Capture Microscopy and Nanoelectrospray/Tandem Mass Spectrometry. Biochemistry, 2006, 45, 9849-9856.	2.5	33
49	Interlaboratory Comparison of Assessments of Alzheimer Disease-Related Lesions: A Study of the BrainNet Europe Consortium. Journal of Neuropathology and Experimental Neurology, 2006, 65, 740-757.	1.7	95
50	Lack of replication of association findings in complex disease: an analysis of 15 polymorphisms in prior candidate genes for sporadic Alzheimer's disease. European Journal of Human Genetics, 2001, 9, 437-444.	2.8	142
51	The Growth-Associated Protein GAP-43 Is Increased in the Hippocampus and in the Gyrus Cinguli in Schizophrenia. Journal of Molecular Neuroscience, 1999, 13, 101-110.	2.3	49
52	Multiple sclerosis and amyloid deposits in the white matter of the brain. Acta Neuropathologica, 1997, 93, 205-209.	7.7	4
53	Volume and number of neurons of the human hippocampal formation in normal aging and Alzheimer's disease. Journal of Comparative Neurology, 1997, 379, 482-494.	1.6	436
54	Amyloid precursor protein mutation causes Alzheimer's disease in a Swedish family. Neuroscience Letters, 1994, 168, 254-256.	2.1	79

#	Article	IF	Citations
55	Effects of nucleus basalis lesion on muscarinic receptor subtypes. Experimental Brain Research, 1993, 97, 225-32.	1.5	15
56	Deep Brain Stimulation in Non-motor Symptoms of Neurodegenerative Diseases. , 0, , .		2